Mode
Text Size
Log in / Sign up

Axia smartphone application increases ASAS20 response to 51% in patients with axial spondyloarthritisSmartphone app improves quality of life for axial spondyloarthritis

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Consider Axia as a safe nonpharmacological adjunct to improve outcomes and response rates in axSpA patients.

This randomized controlled trial evaluated the impact of Axia, a smartphone application combining personalized exercise therapy, patient education, and disease management, in 186 patients with axial spondyloarthritis (axSpA) on stable pharmacotherapy. The study compared the intervention group to a standard of care control group over a 12-week follow-up period.

Patients using Axia showed statistically significant improvements across multiple secondary outcomes. The BASDAI score improved by -1.508 (P <.001), and the Bath Ankylosing Spondylitis Functional Index improved by -1.139 (P <.001). Quality of life scores also improved in the intervention group by -2.297 (P <.001).

Regarding clinical response rates, the Axia group achieved an ASAS20 response rate of 51% compared to 9% in the control group (P <.001). The ASAS40 response rate was 23% in the intervention group versus 3% in the control group (P <.001). No concerning safety signals were observed during the study.

A primary limitation of this study is its monocentric design. While results are promising, the evidence from a single center may limit generalizability. Axia may serve as an effective nonpharmacological tool to enhance care for patients with axSpA.

How this fits prior evidence

How this fits prior evidence: This finding extends previous evidence regarding nonpharmacological interventions for axial spondyloarthritis. Specifically, it builds upon the finding that long-term personalized exercise therapy shows potential cost-effectiveness for patients with axial spondyloarthritis. While the current study focuses on a digital platform (Axia) rather than just exercise, it reinforces the utility of tailored management strategies in this population.

Living with axial spondyloarthritis often means dealing with persistent pain and physical limitations. While medication is a standard part of treatment, finding ways to improve daily life and mobility is just as important for long-term well-being.

A study of 186 patients found that using a smartphone app called Axia led to better outcomes than standard care alone over 12 weeks. The app provided personalized exercise therapy, patient education, and tools for managing the condition. Patients using the app saw significant improvements in their pain scores, physical function, and overall quality of life.

The results showed that those using the app had much higher response rates for clinical goals compared to those receiving standard care. While this was a single-center study, no safety concerns were reported during the trial. It suggests that adding digital tools like Axia can be a safe way to support patients in managing their symptoms.

What this means for you:
A smartphone app providing exercise and education significantly improved quality of life for axial spondyloarthritis patients.

Common questions

How does the Axia app help patients?

The Axia app combines three main features: personalized exercise therapy, patient education, and tools for disease management. In a study of 186 people with axial spondyloarthritis, those using the app saw better scores in pain, physical function, and quality of life over 12 weeks compared to standard care.

Is it safe to use this smartphone application?

No concerning safety signals were observed during the study. The trial suggests that Axia can be a safe non-pharmacological way to improve the state of care for patients with axial spondyloarthritis. You should talk to your doctor about adding digital tools to your current treatment plan.

How much better were the results for those using the app?

Patients using the app showed significantly higher response rates than those on standard care. Specifically, 51% of users reached the ASAS20 goal compared to only 9% in the other group, and 23% reached the ASAS40 goal compared to just 3% in the standard care group.

Study Details

Study typeRct
Sample sizen = 200
EvidenceLevel 2
Follow-up2.8 mo
PublishedAug 2026
View Original Abstract ↓
OBJECTIVES: No app-based nonpharmacological intervention has yet demonstrated to meaningfully improve disease activity, functional status, and disease-specific quality of life in axial spondyloarthritis (axSpA). We evaluated Axia, a CE-marked smartphone application designed for axSpA, that combines personalised exercise therapy, patient education, and disease management, supported by gamification for long-term adherence. METHODS: To evaluate its clinical efficacy, a 12-week monocentric randomised controlled interventional trial was conducted involving 200 patients with axSpA with stable pharmacotherapy. Patients were randomised (1:1) to either using Axia (intervention group [IG]) or standard of care (control group [CG]). RESULTS: A total of 186 participants (mean age 50.61 years, 66% females, 56% with radiographic axSpA, mean Bath Ankylosing Spondylitis Disease Activity Index [BASDAI] 5.17, and 58% received biologicals or Janus kinase inhibitors) completed the study (95 in the IG and 91 in the CG). Compared to CG, participants in the IG demonstrated significant improvements in BASDAI (analysis of covariance [ANCOVA]-estimated group difference: -1.508, P < .001), Bath Ankylosing Spondylitis Functional Index (-1.139; P < .001), and Ankylosing Spondylitis Quality of Life questionnaire (-2.297; P < .001), all exceeding minimal clinically important difference thresholds. A significantly higher proportion of patients in the IG achieved an Assessment of Spondyloarthritis International Society (ASAS)20 response compared to the CG (51% vs 9%; P < .001), and the ASAS40 response rate was also higher (23% vs 3%; P < .001). No concerning safety signals were observed. CONCLUSIONS: These findings support the potential of Axia as a safe and effective nonpharmacological intervention to further improve the state of care of patients with axSpA in addition to conventional anti-inflammatory pharmacotherapy.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.